WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance
Authors
Keywords
-
Journal
Scientific Reports
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-03-06
DOI
10.1038/srep43517
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
- (2016) M. L. Telli et al. CLINICAL CANCER RESEARCH
- Cisplatin resistance and opportunities for precision medicine
- (2016) Lauren Amable PHARMACOLOGICAL RESEARCH
- A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes
- (2015) Qiao Li et al. CANCER BIOLOGY & THERAPY
- Anticancer Effects of Mesothelin-Targeted Immunotoxin Therapy Are Regulated by Tyrosine Kinase DDR1
- (2015) Fatima Ali-Rahmani et al. CANCER RESEARCH
- Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer
- (2015) Giuseppe Cancello et al. Clinical Breast Cancer
- Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification
- (2015) Fouzia Guestini et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Clinical Significance of a Point Mutation in DNA Polymerase Beta (POLB) Gene in Gastric Cancer
- (2015) Xiaohui Tan et al. International Journal of Biological Sciences
- Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
- (2015) Xiaofeng Zheng et al. NATURE
- Exploiting replicative stress to treat cancer
- (2015) Matthias Dobbelstein et al. NATURE REVIEWS DRUG DISCOVERY
- Variation in cancer risk among tissues can be explained by the number of stem cell divisions
- (2015) C. Tomasetti et al. SCIENCE
- Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients
- (2014) T. Byrski et al. BREAST CANCER RESEARCH AND TREATMENT
- Synergistic Therapeutic Effect of Cisplatin and Phosphatidylinositol 3-Kinase (PI3K) Inhibitors in Cancer Growth and Metastasis ofBrca1Mutant Tumors
- (2014) Athanassios Vassilopoulos et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Wee-1 Kinase Inhibition Overcomes Cisplatin Resistance Associated with High-Risk TP53 Mutations in Head and Neck Cancer through Mitotic Arrest Followed by Senescence
- (2014) A. A. Osman et al. MOLECULAR CANCER THERAPEUTICS
- WEE1 murine deficiency induces hyper-activation of APC/C and results in genomic instability and carcinogenesis
- (2014) A Vassilopoulos et al. ONCOGENE
- Systems biology of cisplatin resistance: past, present and future
- (2014) L Galluzzi et al. Cell Death & Disease
- Epithelial-to-mesenchymal transition: What is the impact on breast cancer stem cells and drug resistance
- (2013) Paraskevi Mallini et al. CANCER TREATMENT REVIEWS
- ATR Prohibits Replication Catastrophe by Preventing Global Exhaustion of RPA
- (2013) Luis Ignacio Toledo et al. CELL
- Cisplatin Sensitivity Mediated by WEE1 and CHK1 Is Mediated by miR-155 and the miR-15 Family
- (2012) L. M. Pouliot et al. CANCER RESEARCH
- Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients
- (2012) Balázs Győrffy et al. ENDOCRINE-RELATED CANCER
- Cyclin-Dependent Kinase Suppression by WEE1 Kinase Protects the Genome through Control of Replication Initiation and Nucleotide Consumption
- (2012) H. Beck et al. MOLECULAR AND CELLULAR BIOLOGY
- Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
- (2012) Marieke Aarts et al. Cancer Discovery
- RNAi Screening Identifies TAK1 as a Potential Target for the Enhanced Efficacy of Topoisomerase Inhibitors
- (2011) S. E. Martin et al. CURRENT CANCER DRUG TARGETS
- Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication
- (2011) C. S. Sorensen et al. NUCLEIC ACIDS RESEARCH
- Molecular mechanisms of cisplatin resistance
- (2011) L Galluzzi et al. ONCOGENE
- “Targeting” Triple-Negative Breast Cancer: The Lessons Learned From BRCA1-Associated Breast Cancers
- (2011) Rita Nanda SEMINARS IN ONCOLOGY
- Other Options in the Treatment of Advanced Breast Cancer
- (2011) Melody A. Cobleigh SEMINARS IN ONCOLOGY
- Clusters, factories and domains
- (2010) Peter J. Gillespie et al. CELL CYCLE
- Platinum-DNA Interactions and Subsequent Cellular Processes Controlling Sensitivity to Anticancer Platinum Complexes
- (2010) Saeed Ahmad CHEMISTRY & BIODIVERSITY
- Quantifying colocalization by correlation: The Pearson correlation coefficient is superior to the Mander's overlap coefficient
- (2010) Jeremy Adler et al. CYTOMETRY PART A
- EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
- (2010) A Singh et al. ONCOGENE
- An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients
- (2009) Balazs Györffy et al. BREAST CANCER RESEARCH AND TREATMENT
- Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
- (2009) T. Arumugam et al. CANCER RESEARCH
- Cisplatin plus Gemcitabine Chemotherapy in Taxane/Anthracycline-Resistant Metastatic Breast Cancer
- (2009) Isıl Somali et al. CHEMOTHERAPY
- The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
- (2008) Sendurai A. Mani et al. CELL
- The Role of Cellular Accumulation in Determining Sensitivity to Platinum-Based Chemotherapy
- (2007) Matthew D. Hall et al. Annual Review of Pharmacology and Toxicology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More